TG Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

TG Therapeutics, Inc. (NASDAQ: TGTX) announced its participation in three virtual investor conferences in June 2021. Executive Chairman and CEO Michael S. Weiss will engage in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1 at 2:00 PM ET, followed by another chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 1:20 PM ET. Additionally, Weiss will present at the Raymond James Human Health Innovation Conference on June 22 at 10:00 AM ET. Live webcasts will be available on the Company’s website.

NEW YORK, May 27, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its participation at three upcoming virtual investor conferences. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, is scheduled to participate in the following:

• Jefferies Virtual Healthcare Conference: Fireside chat scheduled to take place on Tuesday, June 1, 2021, at 2:00 PM ET
• Goldman Sachs 42^nd Annual Global Healthcare Conference: Fireside chat scheduled to take place on Tuesday, June 8, 2021, at 1:20 PM ET
• Raymond James Human Health Innovation Conference: Presentation scheduled to take place on Tuesday, June 22, 2021, at 10:00 AM ET
  

A live webcast of each presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at https://ir.tgtherapeutics.com/events. Following each event, an archive file will be available for thirty days.

ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQ^® (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has three programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.

UKONIQ^® is a registered trademark of TG Therapeutics, Inc.

CONTACT:

	Investor Relations
	Email: ir@tgtxinc.com
	Telephone: 1.877.575.TGTX (8489), Option 4
	Media Relations:
	Email: media@tgtxinc.com
	Telephone: 1.877.575.TGTX (8489), Option 6

 

FAQ

What are the dates and times for TGTX's virtual investor conferences?

TG Therapeutics (TGTX) will host conferences on June 1 at 2:00 PM ET, June 8 at 1:20 PM ET, and June 22 at 10:00 AM ET.

Who will represent TGTX at the upcoming investor conferences?

Michael S. Weiss, the Executive Chairman and CEO, will represent TG Therapeutics (TGTX) at the conferences.

Where can I watch the TGTX presentations from the investor conferences?

The presentations from TG Therapeutics (TGTX) can be watched live on their website's Events page.

What is the focus of TG Therapeutics, Inc.?

TG Therapeutics focuses on developing and commercializing treatments for B-cell malignancies and autoimmune diseases.

What products does TGTX offer?

TG Therapeutics has received FDA accelerated approval for UKONIQ® for specific types of lymphoma.